Document is current

Article History

Received: 26 April 2021

Accepted: 1 October 2021

First Online: 15 October 2021

Declarations

:

: The study was approved by the institutional review board of the medical faculty of the University of Tübingen (972/2018B02 and 329/2019B01). Written informed consent was obtained from all patients at the University hospital in Tübingen.

: Not applicable.

: C.K. declares no conflicts of interest.J.S. declares no conflicts of interest.E.D. declares no conflicts of interest.L.N. declares no conflicts of interest.L.H. declares no conflicts of interest.M.L. declares no conflicts of interest.M.R. declares no conflicts of interest.S.K. declares no conflicts of interest.G.T. has served on advisory boards of AbbVie, Bayer and BMS; received consulting fees from AbbVie, Bayer; received speaker fees from Medac and Novocure; received travel grants from Novocure, Medac and BMS; received research grants from Roche Diagnostics and Medac.U.Z. received grants from the German Ministry of Education and Research (BMBF), European Research Council (ERC), Janssen Pharmaceuticals NV and Takeda, and consulting fees from Bayer Vital GmbH and CorTec GmbH, all not related to this work.U.N. declares no conflicts of interest.M.K. receives financial support from Merck, Sanofi-Genzyme, Novartis, Biogen, Celgene and Roche.The funds were not related to the study and the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.